There are 594 resources available
307P - Real-world overall survival among patients with extensive-stage SCLC treated with first-line chemoimmunotherapy in the US
Presenter: Xiuning Le
Session: Poster Display session
308P - Real-world outcomes in extensive-stage small cell lung cancer treated with first-line serplulimab: The nationwide observational ASTRUM-005R study
Presenter: Lin Wu
Session: Poster Display session
309P - Long-term survivors with extensive-stage small-cell lung cancer treated with first-line durvalumab plus carboplatin and etoposide: The CANTABRICO trial
Presenter: Maria Dolores Isla Casado
Session: Poster Display session
310P - Final overall survival (OS) of surufatinib plus PD-1/PD-L1 antibodies as maintenance therapy following first line (1L) platinum-based chemotherapy (Chemo) plus PD-1/PD-L1 antibodies in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC)
Presenter: Yi Hu
Session: Poster Display session
311P - Evaluation of durvalumab real-world use and effectiveness in first line extensive-stage small-cell lung cancer: Primary results of the ARSENAL study
Presenter: Jean Bernard Auliac
Session: Poster Display session
312P - Correlation between immune-related adverse events (irAEs) and survival outcomes in extensive-stage small cell lung cancer (ES-SCLC) patients (pts) treated with chemoimmunotherapy (CT-IO)
Presenter: Federico Monaca
Session: Poster Display session
313P - Baseline PD-L1 expression in circulating neutrophils predicts immune-related adverse events (irAEs) in patients with extensive-stage small-cell lung cancer from CANTABRICO trial
Presenter: Andrés Barba Joaquín
Session: Poster Display session
314P - Predictors of long-term response and survival in patients with extensive stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus chemotherapy in a real-world setting (IFCT-1905 CLINATEZO)
Presenter: Lionel Falchero
Session: Poster Display session
315P - Patient-reported outcomes from CANTABRICO: Durvalumab plus platinum-etoposide in first-line treatment of extensive-stage small cell lung cancer
Presenter: Maria Dolores Isla Casado
Session: Poster Display session
316P - Predictive power of microenvironment YAP-1 and CD31 expression and potential use of EPSILON score in small cell lung cancer (SCLC) treated with chemoimmunotherapy
Presenter: Elisa Roca
Session: Poster Display session
Resources:
Abstract